---
title: COPD
draft: true
---

## What this covers
- Inhalers
- Triple Inhalers
- this is advantageous due to increased risk of severe pneumonia

## Learning objectives
- Inhalers
- Triple Inhalers
- this is advantageous due to increased risk of severe pneumonia
- example of Pharmd led de-prescribing initiative: https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202007-871RL

## Bottom line / summary
- No increase in exacerbation risk for patients stable on triple inhalers (who do not have asthma or eosinophils over 300) to take off the ICS
- this is advantageous due to increased risk of severe pneumonia
- example of Pharmd led de-prescribing initiative: https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202007-871RL

## Approach
1. this is advantageous due to increased risk of severe pneumonia
2. example of Pharmd led de-prescribing initiative: https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202007-871RL
3. COPD

## Red flags / when to escalate
- TODO: List red flags that require urgent escalation.

## Common pitfalls
- No increase in exacerbation risk for patients stable on triple inhalers (who do not have asthma or eosinophils over 300) to take off the ICS

## References
- https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202007-871RL

## Source notes

### COPD
{{< include "../../archive/Clinical Practice Notes/copd.md" >}}

## Source materials
- [Clinical Practice Notes/copd.md](../../archive/Clinical%20Practice%20Notes/copd.md)
